NIH Conflict of Interest Policy for Researchers and Institutions

The NIH conflict of interest framework governs how financial relationships between researchers and outside entities must be disclosed, managed, and in some cases eliminated to protect the integrity of federally funded science. This page covers the regulatory definition of a significant financial interest, the institutional and federal mechanisms for managing conflicts, common disclosure scenarios, and the boundaries that separate manageable conflicts from those requiring elimination. Understanding these requirements is essential for any investigator, research institution, or official engaged with NIH grant programs and funding structures.

Definition and scope

Under 42 CFR Part 50, Subpart F — the federal regulation governing objectivity in research — a significant financial interest (SFI) is defined as a financial interest held by an investigator (or an investigator's spouse or dependent children) that reasonably appears to be related to the investigator's institutional responsibilities. The threshold for most equity interests and income is $5,000 in the prior 12 months from a single publicly traded entity (42 CFR § 50.603).

For interests in non-publicly traded entities, any equity holding — regardless of dollar value — constitutes an SFI. Intellectual property rights and royalties are excluded from the calculation only when they are assigned to the investigator's institution, not held personally.

The policy applies to all investigators who are responsible for the design, conduct, or reporting of research funded by the U.S. Public Health Service (PHS), which includes NIH. Institutions receiving NIH funding are required to maintain a written conflict of interest policy, designate a responsible official, and submit conflict of interest reports to NIH when a financial conflict of interest (FCOI) exists and has been managed, reduced, or eliminated.

How it works

The regulatory framework operates through a three-layer structure:

1. Investigator disclosure — Investigators must disclose all SFIs to their institution at the time of grant application, annually during the award period, and within 30 days of acquiring a new SFI. Disclosure goes to the institution, not directly to NIH.

2. Institutional review and management — The institution's designated official reviews each disclosed SFI to determine whether it constitutes an FCOI (i.e., whether the interest could directly and significantly affect the design, conduct, or reporting of research). If an FCOI is identified, the institution develops a management plan, which may include public disclosure, monitoring of the research, modification of the research plan, disqualification from participation, or divestiture.

3. Federal reporting — When an institution determines that an FCOI exists, it must report that finding to NIH prior to expenditure of any grant funds, or within 60 days if the conflict arises during the award period. NIH retains the authority to review institutional decisions and require additional actions (42 CFR § 50.606).

Institutions are also required to make FCOI information publicly accessible within five business days of a request and to maintain records for at least three years beyond the final expenditure report.

Common scenarios

Four disclosure scenarios arise with particular frequency in NIH-funded research:

• Equity in a startup commercializing research findings — An investigator holds founder's shares in a company whose product is the direct subject of the NIH-funded study. Because the interest is related to the research and exceeds the $5,000 threshold (or is non-publicly traded at any value), this is categorically an FCOI requiring a management plan or, in high-risk cases, elimination.

• Consulting income from a pharmaceutical sponsor — An investigator receives $8,000 in consulting fees from a drug manufacturer while simultaneously conducting an NIH-funded clinical trial evaluating a competing compound. The income exceeds the $5,000 SFI threshold and the relationship is plausibly related to the research scope, triggering full disclosure and institutional review.

• Sponsored travel — Reimbursed or sponsored travel paid by an outside entity is an SFI unless it falls under an exemption for travel sponsored by a federal, state, or local government agency, an institution of higher education, an academic teaching hospital, or a nonprofit research institution. Industry-sponsored travel to advisory board meetings does not fall under this exemption.

• Intellectual property held personally — A patent held personally (not assigned to the institution) on a technology related to the funded research creates an SFI regardless of current royalty income. Income expected from licensing does count toward the $5,000 threshold calculation.

For a broader view of how conflict rules interact with NIH's overall regulatory environment, see the NIH policies and regulations overview.

Decision boundaries

Not every financial relationship triggers management requirements. The critical distinction is between an SFI (a disclosure obligation) and an FCOI (a management obligation):

Institutions retain authority to adopt policies more stringent than the federal minimum. A substantial portion of research universities maintain lower dollar thresholds or broader scope definitions than those set in 42 CFR Part 50.

NIH's own intramural program operates under a separate but parallel framework administered by the NIH Ethics Program under the Office of Government Ethics standards (5 CFR Part 2635), which governs federal employees rather than grantee institutions. Researchers interested in how conflict rules apply to intramural versus extramural settings can review the NIH intramural vs. extramural research comparison for structural context.